(Q50933613)

25 March 2018

title

Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. (English)

1 reference

25 March 2018

author name string

B F Chu

1

1 reference

25 March 2018

M J Karpenko

2

1 reference

25 March 2018

Z Liu

3

1 reference

25 March 2018

J Aimiuwu

4

1 reference

25 March 2018

M A Villalona-Calero

5

1 reference

25 March 2018

K K Chan

6

1 reference

25 March 2018

M R Grever

7

1 reference

25 March 2018

G A Otterson

8

1 reference

25 March 2018

publication date

9 October 2012

1 reference

25 March 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

25 March 2018

volume

71

1 reference

25 March 2018

issue

1

1 reference

25 March 2018

page(s)

115-121

1 reference

25 March 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

A decade of exploring the cancer epigenome - biological and translational implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Targeting the epigenome for the treatment and prevention of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

DNA methylation and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Clinical and molecular responses in lung cancer patients receiving Romidepsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Development of histone deacetylase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Decitabine--bedside to bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1986-8

10.1007/S00280-012-1986-8

21 January 2018

Identifiers

DOI

1 reference

25 March 2018

1 reference

25 March 2018